Fact checked by Nick Blackmer I was first told that I was at higher risk for fatty liver disease in 2005. I had never heard ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

Aroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due ...

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...